In particular, sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown strong renoprotective effects that were not seen with previous antidiabetic agents,3, –5 suggesting that mechanisms unrelated to hyperglycemia may be involved in the pathogenesis of DKD. The gene discussed is SLC5A2; the disease is Hyperglycemia.